Evestra’s management team is led by Ze’ev Shaked, Ph.D., co-founder, President & CEO and Board member. Klaus Nickisch, Ph.D., co-founder of the company and Board member, serves as its Chief Scientific Officer. The company has established a wholly-owned subsidiary in Germany, and Dr. Nickisch serves as the Managing Director of Evestra’s GmbH affiliate.
Dr. Shaked has extensive managerial and pharmaceutical product development experience in commercializing biologics and conventional drugs. Before founding Evestra, he was President and CEO of Spherics, Inc. Prior to Spherics, Dr. Shaked was President of ILEX Products, Inc. and Chief Operating Officer of ILEX Oncology, Inc. where he helped to reshape the product pipeline and led the product development team. Dr. Shaked has held a number of senior R&D and corporate management positions at ImmuLogic Pharmaceutical Corp., Berlex Biosciences, Inc., Triton Biosciences, Inc., CODON Corp. and Chiron Corp. He obtained his Ph.D. in organic and applied biochemistry from MIT.
Ze’ev Shaked, Ph.D. - President & CEO, Evestra, Inc.
Klaus Nickisch, Ph.D. - CSO & Executive Vice President, Evestra, Inc.; Managing Director, Evestra GmbH
Dr. Nickisch enjoyed more than 28 years of experience with Schering AG in a wide range of positions before the acquisition of Schering by Bayer. Dr. Nickisch joined Schering AG as a medicinal chemist and worked on various steroid research projects for five years. He moved from research to development and headed the chemical development function for a number of years. He then moved into project management and led numerous projects in oncology and female health. Dr. Nickisch then joined the business unit Specialized Therapeutics at Berlex as head of project and portfolio management and was promoted to the head of global project management. He completed his studies at the Technical University Berlin with a Ph.D. in organic chemistry.